Centessa Pharmaceuticals Announces Additional 18-Months of Continued Treatment Data from Open-Label Extension (OLE) of Phase 2a Study of SerpinPC for Hemophilia
- Oral presentation at American Society of Hematology (ASH) Annual Meeting highlights continued favorable safety and tolerability profile and sustained long-term efficacy results for SerpinPC:
- 93% reduction in median ABR for both all-bleeds and spontaneous joint bleeds in highest dose tested
- No thromboembolic events or treatment-related sustained elevations of D-dimer observed
- Pivotal program for SerpinPC in hemophilia B advancing; PRESent-5 observation study to begin in the coming weeks